# Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02786927** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 214 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Placebo ELLIPTA device
- **DRUG:** Placebo capsules for use in HANDIHALER device
- **OTHER:** Inhaler Preference Questionnaire Version 1
- **OTHER:** Inhaler Preference Questionnaire Version 2

## Key facts

- **NCT ID:** NCT02786927
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-21
- **Primary completion:** 2016-10-04
- **Final completion:** 2016-10-04
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786927, "Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02786927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*